REVIEW article
Front. Cell. Infect. Microbiol.
Sec. Clinical Infectious Diseases
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1659211
This article is part of the Research TopicPerspectives in Clinical Infectious Diseases: 2024/2025View all 16 articles
Rheumatic Diseases and Latent Tuberculosis Infection in Children: Diagnostic and Therapeutic Challenges
Provisionally accepted
- Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Latent tuberculosis infection (LTBI) is a state of sustained immune response to Mycobacterium tuberculosis (MTB) antigens, without clinical evidence of active tuberculosis. Rheumatic diseases, a common type of autoimmune disease, are often treated with glucocorticoids, immunosuppressants, biologics, and small-molecule targeted drugs. These medications can cause immune dysfunction in patients, increasing the risk of latent tuberculosis reactivation. Children with rheumatic diseases are particularly susceptible to MTB due to their immature immune systems, the nature of their rheumatic disease, and the use of anti-rheumatic medications. This susceptibility makes LTBI more likely to progress to active tuberculosis. Therefore, it is crucial to prioritize LTBI screening in children with rheumatic diseases, identify LTBI promptly, and initiate preventive antituberculosis treatment to prevent the onset of active tuberculosis and ensure the health of children with rheumatic diseases. This article discusses the susceptibility mechanisms, diagnostic methods, and preventive antituberculosis treatment strategies for children with rheumatic diseases and LTBI, aiming to reduce the risk of progression to active tuberculosis and improve patient outcomes.
Keywords: Rheumatic Diseases, Children, latent tuberculosis infection, diagnosis, prophylactic treatment
Received: 03 Jul 2025; Accepted: 08 Sep 2025.
Copyright: © 2025 Li, Chen and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiang Yuan Chen, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.